Stryker Reports Miss on Both Revenue and Earnings in Q1
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 30 2026
0mins
Should l Buy SYK?
Source: seekingalpha
- Earnings Miss: Stryker reported a miss on both revenue and earnings in its Q1 2024 results, with revenue at $6 billion reflecting only a 2.6% year-over-year increase, indicating potential weakness in market demand that could affect investor confidence going forward.
- Decline in EPS: The adjusted EPS of $2.60 fell from $2.84 year-over-year, missing expectations by $0.38, which highlights challenges in cost management and profitability that the company is currently facing.
- Cash Flow Concerns: As of March 31, 2026, Stryker's cash and cash equivalents stood at approximately $2.9 billion, down from $4 billion on December 31, 2025, suggesting a need for improved liquidity management to navigate future uncertainties.
- Guidance Maintained: Despite the disappointing Q1 performance, Stryker has maintained its 2026 EPS guidance of $14.90 to $15.10, reflecting confidence in long-term growth prospects, with organic sales growth projected between 8% and 9.5%.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SYK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SYK
Wall Street analysts forecast SYK stock price to rise
20 Analyst Rating
17 Buy
3 Hold
0 Sell
Strong Buy
Current: 294.230
Low
390.00
Averages
430.32
High
465.00
Current: 294.230
Low
390.00
Averages
430.32
High
465.00
About SYK
Stryker Corporation is a medical technology company. It offers products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Its segments include MedSurg and Neurotechnology and Orthopaedics. Its MedSurg products include surgical equipment, patient and caregiver safety technologies, and navigation systems (Instruments), endoscopic and communications systems (Endoscopy), and patient handling, emergency medical equipment, intensive care disposable products and clinical communication and artificial intelligence-assisted virtual care platform technology (Medical). Neurotechnology includes neurosurgical, neurovascular and craniomaxillofacial implant products. Its Orthopaedics primarily include implants used in total joint replacements, such as hip, knee and shoulder, and others. It offers solutions for venous thromboembolism clot removal without the use of thrombolytic drugs. It is also focused on treating calcified arterial disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Analysis of Stryker Corporation's Profit Outlook
- Profit Impact Analysis: Stryker Corporation's profits were reduced by $684 million due to unusual items over the past year; however, analysts believe these expenses may be one-off, suggesting potential for future profit improvement.
- Future Profit Expectations: Assuming no similar unusual expenses arise in the future, Stryker is expected to see a significant profit increase next year, reflecting an optimistic outlook for the company's earnings potential.
- Earnings Per Share Growth: Over the past three years, Stryker's earnings per share have grown at an annual rate of 26%, indicating a sustained improvement in profitability despite facing short-term challenges.
- Risk Warning: While the profit outlook appears positive, analysts have identified one warning sign that investors should monitor to gain a comprehensive understanding of Stryker's financial health.
See More
DFUS Stock Price Analysis and ETF Dynamics
- Price Fluctuation Analysis: DFUS's 52-week low is $60.87 per share, with a high of $80.095, and the last trade at $80.04 indicates the stock is nearing its peak, potentially attracting investor interest.
- Technical Analysis Tool: Comparing DFUS's latest share price to the 200-day moving average can provide valuable insights for investors, aiding in market trend assessments.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting market liquidity.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF shares outstanding focuses on those experiencing notable inflows (new units created) or outflows (old units destroyed), assessing their impact on underlying assets.
See More
U.S. Stocks Close: S&P 500 Hits All-Time High
- S&P 500 Strong Performance: The S&P 500 index rose by 0.29%, reaching an all-time high, driven by Apple's forecast of stronger-than-expected Q2 revenue, which boosted market sentiment and indicated increased investor confidence in tech stocks.
- Atlassian Stock Surge: Atlassian's stock soared over 29% after reporting Q3 revenue of $1.79 billion, exceeding the market expectation of $1.69 billion, highlighting a robust recovery in the software sector that may attract more investor interest.
- Oil Price Volatility Impacting Markets: WTI crude oil prices fell more than 3%, easing inflation concerns, although trade tensions resurfaced with President Trump's threat to raise tariffs on EU auto imports, potentially negatively affecting market sentiment.
- Economic Data Influencing Stocks: The April ISM manufacturing index remained unchanged at 52.7, below the expected 53.2, indicating signs of economic slowdown, despite the majority of companies reporting Q1 earnings that exceeded expectations, leaving the overall market facing uncertainty.
See More
Mixed Performance in US Indices as Apple’s Strong Earnings Boost Market
- Apple's Strong Earnings: Apple Inc. (AAPL) reported Q2 revenue of $111.18 billion, exceeding the consensus of $109.66 billion, and forecasted Q3 revenue growth of 14% to 17%, significantly above the expected 9.1%, which propelled the Dow Jones Industrial Average up over 4%.
- Software Stocks Surge: Atlassian (TEAM) posted Q3 revenue of $1.79 billion, surpassing the consensus of $1.69 billion, leading to a stock price increase of over 20%, which not only boosted the software sector but also enhanced investor confidence in tech stocks.
- Oil Price Volatility: WTI crude oil prices fell more than 3% due to developments in the US-Iran agreement, temporarily easing inflation concerns and contributing to stock market gains, highlighting the energy market's influence on the overall economy.
- Weak Manufacturing Data: The April ISM manufacturing index remained unchanged at 52.7, below the expected 53.2, while the prices paid sub-index rose to a four-year high of 84.6, indicating increasing price pressures that could impact Federal Reserve policy decisions.
See More
Stryker Q1 2026 Earnings Call Insights
- Cyber Incident Impact: CEO Kevin Lobo stated that the cyber incident significantly impacted Q1 results, causing distortions that are expected to normalize over the year, demonstrating the company's resilience in crisis management.
- Sales Growth Performance: Despite the cyber incident, Stryker reported organic sales growth of 2.4% in Q1, with 1.9% growth in the U.S. and 3.9% internationally, indicating strong demand across global markets.
- Acquisition Plans: Stryker announced its agreement to acquire Amplitude Vascular Systems, expected to close in Q2, which will expand treatment options for peripheral vascular customers and enhance its competitive position in the cardiovascular market.
- Financial Outlook: Despite challenges, Stryker maintains its full-year guidance for 2026, projecting organic net sales growth between 8% and 9.5% and adjusted earnings per share between $14.90 and $15.10, reflecting management's confidence in future performance.
See More
Stryker Reports Miss on Both Revenue and Earnings in Q1
- Earnings Miss: Stryker reported a miss on both revenue and earnings in its Q1 2024 results, with revenue at $6 billion reflecting only a 2.6% year-over-year increase, indicating potential weakness in market demand that could affect investor confidence going forward.
- Decline in EPS: The adjusted EPS of $2.60 fell from $2.84 year-over-year, missing expectations by $0.38, which highlights challenges in cost management and profitability that the company is currently facing.
- Cash Flow Concerns: As of March 31, 2026, Stryker's cash and cash equivalents stood at approximately $2.9 billion, down from $4 billion on December 31, 2025, suggesting a need for improved liquidity management to navigate future uncertainties.
- Guidance Maintained: Despite the disappointing Q1 performance, Stryker has maintained its 2026 EPS guidance of $14.90 to $15.10, reflecting confidence in long-term growth prospects, with organic sales growth projected between 8% and 9.5%.
See More
Analysis of Stryker Corporation's Profit Outlook
- Profit Impact Analysis: Stryker Corporation's profits were reduced by $684 million due to unusual items over the past year; however, analysts believe these expenses may be one-off, suggesting potential for future profit improvement.
- Future Profit Expectations: Assuming no similar unusual expenses arise in the future, Stryker is expected to see a significant profit increase next year, reflecting an optimistic outlook for the company's earnings potential.
- Earnings Per Share Growth: Over the past three years, Stryker's earnings per share have grown at an annual rate of 26%, indicating a sustained improvement in profitability despite facing short-term challenges.
- Risk Warning: While the profit outlook appears positive, analysts have identified one warning sign that investors should monitor to gain a comprehensive understanding of Stryker's financial health.
See More
DFUS Stock Price Analysis and ETF Dynamics
- Price Fluctuation Analysis: DFUS's 52-week low is $60.87 per share, with a high of $80.095, and the last trade at $80.04 indicates the stock is nearing its peak, potentially attracting investor interest.
- Technical Analysis Tool: Comparing DFUS's latest share price to the 200-day moving average can provide valuable insights for investors, aiding in market trend assessments.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting market liquidity.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF shares outstanding focuses on those experiencing notable inflows (new units created) or outflows (old units destroyed), assessing their impact on underlying assets.
See More
U.S. Stocks Close: S&P 500 Hits All-Time High
- S&P 500 Strong Performance: The S&P 500 index rose by 0.29%, reaching an all-time high, driven by Apple's forecast of stronger-than-expected Q2 revenue, which boosted market sentiment and indicated increased investor confidence in tech stocks.
- Atlassian Stock Surge: Atlassian's stock soared over 29% after reporting Q3 revenue of $1.79 billion, exceeding the market expectation of $1.69 billion, highlighting a robust recovery in the software sector that may attract more investor interest.
- Oil Price Volatility Impacting Markets: WTI crude oil prices fell more than 3%, easing inflation concerns, although trade tensions resurfaced with President Trump's threat to raise tariffs on EU auto imports, potentially negatively affecting market sentiment.
- Economic Data Influencing Stocks: The April ISM manufacturing index remained unchanged at 52.7, below the expected 53.2, indicating signs of economic slowdown, despite the majority of companies reporting Q1 earnings that exceeded expectations, leaving the overall market facing uncertainty.
See More
Mixed Performance in US Indices as Apple’s Strong Earnings Boost Market
- Apple's Strong Earnings: Apple Inc. (AAPL) reported Q2 revenue of $111.18 billion, exceeding the consensus of $109.66 billion, and forecasted Q3 revenue growth of 14% to 17%, significantly above the expected 9.1%, which propelled the Dow Jones Industrial Average up over 4%.
- Software Stocks Surge: Atlassian (TEAM) posted Q3 revenue of $1.79 billion, surpassing the consensus of $1.69 billion, leading to a stock price increase of over 20%, which not only boosted the software sector but also enhanced investor confidence in tech stocks.
- Oil Price Volatility: WTI crude oil prices fell more than 3% due to developments in the US-Iran agreement, temporarily easing inflation concerns and contributing to stock market gains, highlighting the energy market's influence on the overall economy.
- Weak Manufacturing Data: The April ISM manufacturing index remained unchanged at 52.7, below the expected 53.2, while the prices paid sub-index rose to a four-year high of 84.6, indicating increasing price pressures that could impact Federal Reserve policy decisions.
See More
Stryker Q1 2026 Earnings Call Insights
- Cyber Incident Impact: CEO Kevin Lobo stated that the cyber incident significantly impacted Q1 results, causing distortions that are expected to normalize over the year, demonstrating the company's resilience in crisis management.
- Sales Growth Performance: Despite the cyber incident, Stryker reported organic sales growth of 2.4% in Q1, with 1.9% growth in the U.S. and 3.9% internationally, indicating strong demand across global markets.
- Acquisition Plans: Stryker announced its agreement to acquire Amplitude Vascular Systems, expected to close in Q2, which will expand treatment options for peripheral vascular customers and enhance its competitive position in the cardiovascular market.
- Financial Outlook: Despite challenges, Stryker maintains its full-year guidance for 2026, projecting organic net sales growth between 8% and 9.5% and adjusted earnings per share between $14.90 and $15.10, reflecting management's confidence in future performance.
See More
Stryker Reports Miss on Both Revenue and Earnings in Q1
- Earnings Miss: Stryker reported a miss on both revenue and earnings in its Q1 2024 results, with revenue at $6 billion reflecting only a 2.6% year-over-year increase, indicating potential weakness in market demand that could affect investor confidence going forward.
- Decline in EPS: The adjusted EPS of $2.60 fell from $2.84 year-over-year, missing expectations by $0.38, which highlights challenges in cost management and profitability that the company is currently facing.
- Cash Flow Concerns: As of March 31, 2026, Stryker's cash and cash equivalents stood at approximately $2.9 billion, down from $4 billion on December 31, 2025, suggesting a need for improved liquidity management to navigate future uncertainties.
- Guidance Maintained: Despite the disappointing Q1 performance, Stryker has maintained its 2026 EPS guidance of $14.90 to $15.10, reflecting confidence in long-term growth prospects, with organic sales growth projected between 8% and 9.5%.
See More
